Showing 611-620 of 650 results for "".
- ThermiGen, an Almirall company, Names Vladimir Paul-Blanc President & General Managerhttps://practicaldermatology.com/news/thermigen-an-almirall-company-names-vladimir-paul-blanc-president-general-manager/2458219/Vladimir Paul-Blanc has been named President & General Manager of ThermiGen, LLC, starting May 1. He will report directly to the Executive Vice-president of Commercial Strategy of Almirall, Alfonso Ugarte, and he will be responsible for all general management responsibilities for the Thermi b
- La Roche-Posay Debuts New Prebiotic Skincare Linehttps://practicaldermatology.com/news/la-roche-posay-debuts-new-prebiotic-skincare-line/2458323/La Roche-Posay is rolling out a new prebiotic Skincare Line. TOLERIANE Double Repair Moisturizer comes in a full line of products, including an SPF version and two complementary cleansers. The skin's microbiome is comprised of more than 100 b
- Biofrontera Launches Ameluz for Actinic Keratosishttps://practicaldermatology.com/news/biofrontera-launches-ameluz-for-actinic-keratosis/2458397/Biofrontera AG initiated the US commercial launch of its combination topical prescription drug Ameluz and medical device BF-RhodoLED, which has been FDA approved to treat mild to moderate actinic keratosis (AK) on the face and scalp. Ameluz is used in combination with the medical device B
- Is 'Mitoiron Claw' the Next Great Sunscreen Ingredient?https://practicaldermatology.com/news/is-mitoiron-claw-the-next-great-sunscreen-ingredient/2458493/A new compound that blocks excess free iron in the mitochondria may offer dramatic protection against Ultraviolet A (UVA) radiation in sunlight, according to scientists at the University of Bath and King's College London. Most sunscreens protect well against solar Ultraviolet B
- SPF30 Sunscreens Delay Melanoma Onset in Mouse Modelhttps://practicaldermatology.com/news/spf30-sunscreens-delay-melanoma-onset-in-mouse-model/2458601/Applying sun protection factor 30 (SPF30) sunscreen prior to exposure to ultraviolet-B (UVB) light delayed melanoma onset in a mouse model, report researchers from The Ohio State University Comprehensive Cancer Center Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. S
- ALASTIN™ Skincare, Inc. Announces New Scientific Advisory Councilhttps://practicaldermatology.com/news/alastin-skincare-inc-announces-new-scientific-advisory-council/2458667/ALASTIN™ Skincare, Inc., announced its new eight-person Scientific Advisory Council. The Council includes: · Vivian Bucay, M.D., Dermatologist, B
- Valeant Pharmaceuticals Announces Management And Business Updatehttps://practicaldermatology.com/news/valeant-pharmaceuticals-announces-management-and-business-update/2458677/J. Michael Pearson has returned as Valeant Pharmaceuticals International, Inc.’s chief executive officer following his recovery from severe pneumonia and other complications. Howard B. Schiller, Valeant's interim chief executive officer, will transition out of his current duties but wil
- Novan Announces Robert A. Ingram as Chairmanhttps://practicaldermatology.com/news/novan-announces-robert-a-ingram-as-chairman/2458716/Novan, Inc. named Robert A. Ingram as Chairman of the Board of Directors of Novan. In addition, Robert Keegan has been appointed to the Board of Directors. The company also announced that it received $32.8 million of net proceeds in a private Mezzanine B financing in December 2015 from it
- Dr. Reddy's and its Subsidiary Promius Pharma File Three NDAshttps://practicaldermatology.com/news/dr-reddys-and-its-subsidiary-promius-pharma-announce-filing-of-three-ndas/2458971/Dr. Reddy's Laboratories and its subsidiary, Promius Pharma, LLC filed three 505(b)(2) New Drug Applications (NDAs) with the FDA. The three NDAs - DFD-01, DFD-09, and DFN-11, are in support of Dr. Reddy’s Proprietary Products group, focused on developing and commercializing therapies in
- CMS Assigns Q-code to Fish Skin Technology, Kerecis Reportshttps://practicaldermatology.com/news/20141113-cms_assigns_q-code_to_fish_skin_technology_kerecis_reports/2459065/The new Omega3 tissue-regeneration material from Kerecis Limited—dubbed fish skin—has received a "Q" code from the Centers for Medicare and Medicaid Services (CMS). Kerecis Omega3 Wound, indicated for the management of chronic wounds including diabetic, vascular and other hard-to-heal wounds, has b